[{"data":1,"prerenderedAt":221},["ShallowReactive",2],{"drug-cabergoline":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":36,"contraindications":94,"warnings":112,"renal":113,"monitoring":114,"interactions":115,"review":116,"examples":119,"atc":133,"iran":135,"links":159,"populations":180,"usApproval":216},"cabergoline",1,{"fa":7,"en":8},"کابرگولین","Cabergoline","genitourinary-sex-hormones",{"fa":11,"en":12},"آگونیست دوپامین","Dopamine agonist",[14],{"name":15,"market":16},"Dostinex","US",[18,19,7,20],"dostinex","دوستینکس","پرولاکتین",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-0-5","tablet","oral","0.5 mg tablet (scored)",{"amount":28,"unit":29,"perUnit":24,"scored":30},0.5,"mg",true,[16],[33],{"source":34,"section":35},"fda-cabergoline","3",[37,61,75],{"id":38,"disease":39,"label":40,"population":43,"type":47,"unit":29,"dose":48,"refs":50,"notes":53},"prl","hyperprolactinemia",{"fa":41,"en":42},"هیپرپرولاکتینمی — ۰٫۲۵ mg دو بار در هفته","Hyperprolactinaemia — 0.25 mg twice weekly",{"minAge":44},{"value":45,"unit":46},18,"year","fixed",{"perDose":49,"dosesPerDay":5},0.25,[51],{"source":34,"section":52},"2.2",[54],{"text":55,"refs":58},{"fa":56,"en":57},"دو بار در هفته (نه روزانه). افزایش ۰٫۲۵ mg دو بار در هفته با فاصله‌ها تا طبیعی شدن پرولاکتین.","Twice weekly (not daily). Increase by 0.25 mg twice weekly at intervals until prolactin normalises.",[59],{"source":34,"section":60},"2",{"id":62,"disease":63,"label":64,"population":67,"type":47,"unit":29,"dose":69,"refs":70,"durationDays":74},"lact-inhibit","lactation-suppression",{"fa":65,"en":66},"جلوگیری از شیردهی — ۱ mg (۲ قرص ۰٫۵) یک‌جا در روز اول پس از زایمان","Inhibition of lactation — 1 mg (two 0.5 mg tablets) once on the first day postpartum",{"minAge":68},{"value":45,"unit":46},{"perDose":5,"dosesPerDay":5},[71],{"source":72,"section":73},"uk-dostinex","4.2",{"min":5,"max":5},{"id":76,"disease":63,"label":77,"population":80,"type":47,"unit":29,"dose":82,"refs":84,"durationDays":86,"notes":87},"lact-suppress",{"fa":78,"en":79},"قطع شیردهی برقرارشده — ۰٫۲۵ mg هر ۱۲ ساعت، ۲ روز","Suppression of established lactation — 0.25 mg every 12 h for 2 days",{"minAge":81},{"value":45,"unit":46},{"perDose":49,"dosesPerDay":83},2,[85],{"source":72,"section":73},{"min":83,"max":83},[88],{"text":89,"refs":92},{"fa":90,"en":91},"این رژیم نسبت به دوز یک‌جا بهتر تحمل می‌شود (افت فشار کمتر). همراه غذا.","Better tolerated than the single dose (less hypotension). With food.",[93],{"source":72,"section":73},[95,104],{"id":96,"severity":97,"text":98,"refs":101},"ci","block",{"fa":99,"en":100},"فشار خون کنترل‌نشده؛ حساسیت به مشتقات ارگوت؛ سابقه بیماری دریچه قلب؛ سابقه فیبروز ریه، پریکارد یا رتروپریتوئن.","Uncontrolled hypertension; hypersensitivity to ergot derivatives; history of cardiac valvulopathy; history of pulmonary, pericardial or retroperitoneal fibrosis.",[102],{"source":34,"section":103},"4",{"id":105,"severity":97,"text":106,"refs":109},"uk-ci",{"fa":107,"en":108},"حساسیت به ارگوت‌ها؛ سابقه فیبروز ریه، پریکارد یا رتروپریتوئن؛ نارسایی کبد؛ توکسمی بارداری؛ مصرف همزمان آنتی‌سایکوتیک؛ سابقه سایکوز پس از زایمان.","Ergot hypersensitivity; history of pulmonary, pericardial or retroperitoneal fibrosis; hepatic insufficiency; toxaemia of pregnancy; concomitant antipsychotics; history of puerperal psychosis.",[110],{"source":72,"section":111},"4.3",[],[],[],[],{"status":117,"reviewer":118,"date":118},"unverified",null,[120,125,130],{"regimen":38,"formulation":23,"input":121,"expect":124},{"ageYears":122,"weightKg":123},30,60,{"perDose":49,"tabletsPerDoseRounded":28},{"regimen":62,"formulation":23,"input":126,"expect":129},{"ageYears":127,"weightKg":128},28,70,{"perDose":5,"tabletsPerDoseRounded":83},{"regimen":76,"formulation":23,"input":131,"expect":132},{"ageYears":127,"weightKg":128},{"perDose":49,"tabletsPerDoseRounded":28},[134],"G02CB03",{"status":136,"forms":137,"refs":154},"registered",[138,142,146,150],{"code":139,"en":140,"fa":141},"02287","CABERGULINE 0.5MG TAB","قرص کابرگولین ۰٫۵ میلی‌گرم",{"code":143,"en":144,"fa":145},"02374","CABERGULINE 1MG TAB","قرص کابرگولین ۱ میلی‌گرم",{"code":147,"en":148,"fa":149},"08822","CABERGULINE 2MG TAB","قرص کابرگولین ۲ میلی‌گرم",{"code":151,"en":152,"fa":153},"08824","CABERGULINE 4MG TAB","قرص کابرگولین ۴ میلی‌گرم",[155],{"source":156,"section":157,"url":158},"darooyab-generic","G-2486\u002FCabergoline","https:\u002F\u002Fwww.darooyab.ir\u002FG-2486\u002FCabergoline",[160,164,168,171,174,176],{"kind":161,"url":162,"label":163},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=220309","ANDA220309",{"kind":165,"url":166,"label":167},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=8562f94f-a59a-4893-aefc-ea6547b01e92","FDA Cabergoline",{"kind":169,"url":170,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa612020.html",{"kind":172,"url":173,"label":134},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=G02CB03",{"kind":175,"url":158,"label":8},"darooyab",{"kind":177,"url":178,"label":179},"emc","https:\u002F\u002Fwww.medicines.org.uk\u002Femc\u002Fproduct\u002F1691\u002Fsmpc","UK Dostinex SmPC",{"pregnancy":181,"lactation":190,"pediatric":199,"geriatric":208},{"level":182,"text":183,"quote":186,"refs":187},"avoid",{"fa":184,"en":185},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Clinical Considerations Maternal Adverse Reactions : In general, avoid use of dopamine agonists, including cabergoline tablets, during pregnancy and the postpartum period.",[188],{"source":34,"section":189},"8.1",{"level":191,"text":192,"quote":195,"refs":196},"caution",{"fa":193,"en":194},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Cabergoline tablets is not recommended in postpartum women who are breastfeeding or who are planning to breastfeed.",[197],{"source":34,"section":198},"8.2",{"level":200,"text":201,"quote":204,"refs":205},"not-established",{"fa":202,"en":203},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness of cabergoline tablets in pediatric patients have not been established.",[206],{"source":34,"section":207},"8.4",{"level":191,"text":209,"quote":212,"refs":213},{"fa":210,"en":211},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical studies of cabergoline tablets did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.",[214],{"source":34,"section":215},"8.5",{"kind":217,"refs":218,"id":163},"ANDA",[219],{"source":34,"section":220},"SPL approval \u002F marketing category",1792191871223]